Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)

A. Martinez Meñaca (Santander, Spain), I. Fernández-Cuesta Peñafiel (Madrid , Spain), I. Blanco Vich (Barcelona, Spain), A. Roman Broto (Barcelona, Spain), J. Cifrian Martinez (Santander, Spain), P. Escribano Subias (Madrid, Spain), R. Lopez Reyes (Valencia, Spain)

Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension
Session: Haemodynamics and chronic thromboembolic pulmonary hypertension
Session type: Thematic Poster
Number: 1442
Disease area: Pulmonary vascular diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Martinez Meñaca (Santander, Spain), I. Fernández-Cuesta Peñafiel (Madrid , Spain), I. Blanco Vich (Barcelona, Spain), A. Roman Broto (Barcelona, Spain), J. Cifrian Martinez (Santander, Spain), P. Escribano Subias (Madrid, Spain), R. Lopez Reyes (Valencia, Spain). Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). 1442

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Comparison of activities of daily living in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH)
Source: International Congress 2016 – Best abstracts in exercise capacity and testing in chronic lung diseases
Year: 2016


Impact of pulmonary arterial hypertension (PAH) on the lives of patients and carers
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013


Incidence and outcomes of haemoptysis in patients with operable and non-operable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH)
Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension
Year: 2016


Comparison of prevalence of diabetes mellitus in patients with idiopathic pulmonary arterial hypertension and distal chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers
Year: 2013


Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010

Prevalence of chronic thromboembolic pulmonary hypertension (CTEPH) in patients after pulmonary embolism
Source: International Congress 2018 – Clinical aspects of pulmonary hypertension
Year: 2018

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Source: Eur Respir J, 53 (6) 1802004; 10.1183/13993003.02004-2018
Year: 2019



Contrasting physiological responses to the six minute walk test in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH)
Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology
Year: 2016


ERS statement on chronic thromboembolic pulmonary hypertension
Source: ERS webinar 2021: ERS statement on chronic thromboembolic pulmonary hypertension
Year: 2021


Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH)
Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension
Year: 2009


Chronic thromboembolic pulmonary hypertension (CTEPH) and beyond
Source: Annual Congress 2011 - Ceremony for Pulmonary Arterial Hypertension Award (supported by Actelion) followed by Pulmonary Hypertension in the Clinic Grand Round - an interactive session
Year: 2011


Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015


Comparison of clinical characteristics in patients with pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease
Year: 2008

Co-morbidities and pulmonary arterial hypertension (PAH) in COPD patients
Source: International Congress 2016 – Comorbidities and exacerbations in COPD
Year: 2016


Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology
Source: Eur Respir Rev 2009; 19: 59-63
Year: 2010



Survival in patients with chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Eur Respir J 2005; 26: Suppl. 49, 272s
Year: 2005

Everyday life experiences of spouses of patients who suffer from pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
Source: ERJ Open Res, 5 (1) 00218-2018; 10.1183/23120541.00218-2018
Year: 2019



Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020
Year: 2020



COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey
Source: ERJ Open Res, 6 (4) 00520-2020; 10.1183/23120541.00520-2020
Year: 2020